Galletta Christopher 4

What Happened
Christopher Galletta, Controller and Principal Accounting Officer of Trevi Therapeutics (TRVI), was granted an option covering 35,000 shares on February 19, 2026. The grant is reported as an award/acquisition (code A) with an acquisition amount shown as $0.00—this reflects a compensation grant of a derivative (an option), not a cash market purchase or sale.

Key Details

• Transaction date: 2026-02-19; Form 4 filed: 2026-02-20 (appears timely).
• Transaction type/code: Award/Grant (A) of an option (derivative).
• Amount: 35,000 shares underlying the option; acquisition amount reported as $0.00.
• Vesting: Per footnote, 35,000 shares vest in equal monthly installments through February 19, 2030, subject to continued service.
• Shares owned after transaction: not specified in the excerpt of the filing.
• Role: Galletta is the company’s Controller and Principal Accounting Officer.

Context
This is a standard equity compensation award: the option gives the right to acquire shares in the future if/when vested and exercised. Because the grant vests monthly over four years, Galletta does not immediately own all 35,000 shares and no immediate sale occurred. Awards like this are common for employee retention and do not, by themselves, indicate an insider buying or selling stock in the open market.